Kymera Therapeutics Investor Relations Material

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. These targeted intracellular proteolytic inhibitors are designed to slow or stop the progression of a variety of serious diseases including cancer and cystic fibrosis. The Company has some marketed products, for example defactinib (Ribomunex), which is approved for the treatment of adults with cystic fibrosis that have a certain genetic mutation; and TRU-016 (Refacto AF) for the treatment of adults with pancreatic ductal adenocarcinoma (PDAC) who have received previous chemotherapy containing gemcitabine and/or erlotinib.